Shionogi keeps arm's length finger in HIV pie as ViiV acquires dolutegravir rights
This article was originally published in Scrip
Executive Summary
As its lead development molecule nears a first regulatory filing by year-end on the back of a positive dataset, the Shionogi-ViiV Healthcare HIV joint venture has solidified commercial plans that involve both the Japanese partner taking a step back and the integrase inhibitor JV itself being dissolved.